Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faldaprevir + PegIFN/RBV in HCV GT1
NCT01608737Phase 3Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2012
- Primary completion
- Oct 2015
- Modality
- Small Molecules, Modified Peptides
01
Overview
A Phase 3 trial of faldaprevir in chronic hepatitis C (CHC), sponsored by Boehringer Ingelheim. Planned start Sep 2012; status: withdrawn.
02
Drugs
faldaprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT01608737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01608737.